Pênfigoide bolhoso induzido por Pembrolizumabe em paciente com câncer gástrico HER2 hiper expresso: relato de caso
Hasmy Abbes; Lucas Soares Almada; Melissa Maeda; Leonardo Oliveira Mendonça; Felipe Moraes Toledo Pereira.
Resumo
O pênfigoide bolhoso (PB) é uma doença autoimune subepidérmica cada vez mais associada ao uso de inibidores de checkpoint imunológico (ICIs), como o pembrolizumabe. Relatamos o caso de um homem de 71 anos com adenocarcinoma gástrico HER2-positivo que desenvolveu PB três meses após iniciar imunoterapia de manutenção. O uso de corticosteroides foi limitado por glaucoma preexistente, sendo necessário iniciar omalizumabe. Apesar de resposta parcial, o quadro evoluiu com recorrências e necessidade de hospitalizações. O PB induzido por ICIs representa um desafio terapêutico, exigindo abordagem individualizada e manejo multidisciplinar para equilibrar controle oncológico e toxicidades imunes.
Palavras-chave
Referências
1. Akbarialiabad H, Schmidt E, Patsatsi A, et al. Bullous pemphigoid. Nat Rev Dis Primers. 2025;11(1):12. https://doi.org/10.1038/s41572-025-00595-5. PMid:39979318.
2. Rosi-Schumacher M, Baker J, Waris J, Seiffert-Sinha K, Sinha AA. Worldwide epidemiologic factors in pemphigus vulgaris and bullous pemphigoid. Front Immunol. 2023;14:1159351. https://doi.org/10.3389/fimmu.2023.1159351. PMid:37180132.
3. Wang J, Hu X, Jiang W, et al. Analysis of the clinical characteristics of pembrolizumab-induced bullous pemphigoid. Front Oncol. 2023;13:1095694. https://doi.org/10.3389/fonc.2023.1095694. PMid:36937423.
4. Apalla Z, Nikolaou V, Fattore D, et al. European recommendations for management of immune checkpoint inhibitors‐ derived dermatologic adverse events. The EADV task force ‘Dermatology for cancer patients’ position statement. J Eur Acad Dermatol Venereol. 2022;36(3):332-50. https://doi.org/10.1111/jdv.17855. PMid:34910332.
5. Wongvibulsin S, Pahalyants V, Kalinich M, et al. Epidemiology and risk factors for the development of cutaneous toxicities in patients treated with immune-checkpoint inhibitors: a United States population-level analysis. J Am Acad Dermatol. 2022;86(3):563-72. https://doi.org/10.1016/j.jaad.2021.03.094. PMid:33819538.
6. Jendoubi F, Sibaud V, Meyer N, et al. Bullous pemphigoid associated with Grover disease: a specific toxicity of anti‐PD‐1 therapies? Int J Dermatol. 2022;61(6):e200-2. https://doi.org/10.1111/ijd.16068. PMid:35073414.
7. Nikolaou VA, Apalla Z, Carrera C, et al. Clinical associations and classification of immune checkpoint inhibitor‐induced cutaneous toxicities: a multicentre study from the European Academy of Dermatology and Venereology Task Force of Dermatology for Cancer Patients. Br J Dermatol. 2022;187(6):962-9. https://doi.org/10.1111/bjd.21781. PMid:35861701.
8. Khazaeli M, Grover R, Pei S. Concomitant nivolumab‐associated Grover disease and bullous pemphigoid in a patient with metastatic renal cell carcinoma. J Cutan Pathol. 2023;50(6):520-3. https://doi.org/10.1111/cup.14383. PMid:36601731.
9. Johnson DB, Nebhan CA, Moslehi JJ, Balko JM. Immune-checkpoint inhibitors: long-term implications of toxicity. Nat Rev Clin Oncol. 2022;19(4):254-67. https://doi.org/10.1038/s41571-022-00600-w. PMid:35082367.
10. Asdourian MS, Shah N, Jacoby TV, Reynolds KL, Chen ST. Association of bullous pemphigoid with immune checkpoint inhibitor therapy in patients with cancer: a systematic review. JAMA Dermatol. 2022;158(8):933-41. https://doi.org/10.1001/jamadermatol.2022.1624. PMid:35612829.
11. Shiravand Y, Khodadadi F, Kashani SMA, et al. Immune checkpoint inhibitors in cancer therapy. Curr Oncol. 2022;29(5):3044-60. https://doi.org/10.3390/curroncol29050247. PMid:35621637.
Submetido em:
12/01/2026
Revisado em:
10/02/2026
Aceito em:
26/02/2026
Facebook
Google+
Twitter
LinkedIn
Mendeley
StumbleUpon
CiteULike
Reddit
Email